Abstract:Anthracyclines, are a class of conventional and routinely used firstline chemotherapy drugs to treat breast cancer. Immunogenic cell death (ICD) is characterized by the exposure of danger signals that promote dendritic cell maturation and antigen presentation and is often associated with the induction of cancer cell-intrinsic IFN-I signaling pathway. In addition, among multiple chemotherapeutic drugs such as doxorubicin (Dox) is well-known to promote tumor immunogenicity by interfering with DNA synthesis. Galectin-9 (Gal-9), as a member of β-galactoside-binding protein family, has been demonstrated to induce T cell death and promote immunosuppression in the tumor microenvironment. In addition, it has been shown that some interferon (IFN) and interleukin (IL) factors can induce Gal-9 expression. However, the mechanism cross-talk between anthracyclines and Gal-9 immunecheckpoint inhibitor remains unknown. Here we show that doxorubicin induces PD-L1 expression in human breast cancer cell lines and animal models. Mechanistically, doxorubicin promoted IFNβ expression, which in turn enhanced doxorubicin-induced Gal-9. Furthermore, we discovered that doxorubicin induces tumor Gal-9 via STING upregulation. The combination of doxorubicin and anti-Gal-9 therapy compared with each agent alone significantly increased the therapeutic efficacy in vivo. Clinically, a higher Gal-9 and p-STING level in the tumor region of after-treatment anthracyclines as compared to before treatment is indicated in breast cancer tumor tissue. Taken together, our study demonstrates crosstalk between anthracyclines-induced ICD and tumor-associated immunosuppression and provides a novel therapeutic strategy by combining anthracyclines and Gal-9 antibody in breast cancer. Citation Format: Xian Sun, Wei-Jan Wang, Jilu Lang, Riyao Yang, Wan-Jou Shen, Linlin Sun, Mien-Chie Hung. Inhibition of STING/Galectin-9 Axis Sensitize Anthracyclines Treatment And Induce Anti-tumor Immunity [abstract]. In: Proceedings of Frontiers in Cancer Science; 2023 Nov 6-8; Singapore. Philadelphia (PA): AACR; Cancer Res 2024;84(8_Suppl) nr P53.

Galectin-9 Promotes a Suppressive Microenvironment in Human Cancer by Enhancing STING Degradation

The Developmental Transcription Factor IRF6 Attenuates ABCG2 Gene Expression and Distinctively Reverses Stemness Phenotype in Nasopharyngeal Carcinoma.

ST6GALNAC4 Promotes Hepatocellular Carcinogenesis by Inducing Abnormal Glycosylation.

STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion

Tumor Cell-Secreted ISG15 Promotes Tumor Cell Migration and Immune Suppression by Inducing the Macrophage M2-Like Phenotype

Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target

Galectin-8 Alters Immune Microenvironment and Promotes Tumor Progression.

Expression of Galectin-1 in Carcinoma-Associated Fibroblasts Promotes Gastric Cancer Cell Invasion Through Upregulation of Integrin Beta 1

Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity

Abstract P53: Inhibition of STING/Galectin-9 Axis Sensitize Anthracyclines Treatment And Induce Anti-tumor Immunity

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

The Dual Role of the NFATc2/galectin-9 Axis in Modulating Tumor-Initiating Cell Phenotypes and Immune Suppression in Lung Adenocarcinoma

Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells

Targeting the STING Pathway in Tumor-Associated Macrophages Regulates Innate Immune Sensing of Gastric Cancer Cells.

Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion

CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer

Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment

Tumor-associated Macrophages Expressing Galectin-9 Identify Immunoevasive Subtype Muscle-Invasive Bladder Cancer with Poor Prognosis but Favorable Adjuvant Chemotherapeutic Response

Abstract 2882: Characteristic immunomodulatory role of myeloid galectin-9 in the brain tumor microenvironment

The miRNA-185-5p/STIM1 Axis Regulates the Invasiveness of Nasopharyngeal Carcinoma Cell Lines by Modulating EGFR Activation-Stimulated Switch from E- to N-Cadherin

Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts